BCAB – bioatla, inc. (US:NASDAQ)
Stock Stats
News
BioAtla (NASDAQ:BCAB) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $4.00 price target on the stock.
BioAtla and GATC Health to advance Oz-V in Phase III trial [Yahoo! Finance]
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) [Yahoo! Finance]
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
Form S-3 BioAtla, Inc.
Form DEFA14A BioAtla, Inc.
Form 8-K BioAtla, Inc. For: Jan 09
Form DEFA14A BioAtla, Inc.
Form 8-K BioAtla, Inc. For: Dec 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.